We are live on ! Find out more
CBMG

Cellular Biomedicine Group, Inc.
CBMG

Delisted

CBMG was delisted on the 19th of February, 2021.

67 hedge funds and large institutions have $80M invested in Cellular Biomedicine Group, Inc. in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 28 increasing their positions, 15 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 15

2% more capital invested

Capital invested by funds: $78.5M → $80M (+$1.55M)

8% less funds holding

Funds holding: 7367 (-6)

50% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 12

68% less call options, than puts

Call options by funds: $529K | Put options by funds: $1.64M

Holders
67
Holders Change
-6
Holders Change %
-8.22%
% of All Funds
1.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
28
Reduced
15
Closed
12
Calls
$529K
Puts
$1.64M
Net Calls
-$1.11M
Net Calls Change
-$420K
Name Holding Trade Value Shares
Change
Change in
Stake
ASN
76
Advisory Services Network
Georgia
-$620 -34 Closed
Simplex Trading
77
Simplex Trading
Illinois
+$471K +25,847 +7,120%

CBMG Hedge Fund Activity: Q4 2020 in Review

67 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q4 2020, worth a combined $80M — up 2% from $78.5M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CBMG and 6 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 28 added.

The largest buyer was Alpine Global Management, adding an estimated $1.73M. The largest seller was Water Island Capital, exiting entirely with an estimated $2.44M sold.

  • 67 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q4 2020, down from 73 in Q3 2020.
  • Funds reported $80M of Cellular Biomedicine Group, Inc. stock for Q4 2020, up 2% quarter-over-quarter.
  • 6 funds opened new Cellular Biomedicine Group, Inc. positions in Q4 2020 and 12 closed out, a net change of -6 holders.
  • The largest Cellular Biomedicine Group, Inc. buyer in Q4 2020 was Alpine Global Management, an estimated $1.73M added.
  • The largest Cellular Biomedicine Group, Inc. seller in Q4 2020 was Water Island Capital, an estimated $2.44M sold.

Based on aggregated 13F filings for Q4 2020.